Skip to main content


IQFish Banner

The IQFISH panel for lung cancer is a set of oligonucleotide-based FISH probes, premixed with IQFISH Buffer, for the detection of rearrangements involving the ALK, ROS1 and RET genes, and the detection of MET gene amplification by fluorescence in situ hybridization (FISH). These probes are to be used on lung paraffin-embedded tissue sections.

Non-Small Cell Lung Cancer (NSCLC) may involce genetic aberrations that can be used to direct therapy. For example, a fusion of ALK with EML4 occurs in about 5% of cancers and is linked to strong patient response to treatment with Crizotinib. Fusions of ROS1 and RET or amplification of MET are also observed with potentioal treatment indication. Identification of these abnormalities is often done using FISH. 

This panel of IQFISH Probes combines new generations of FISH technologies-oligonucleotide-based FISH in a ready-to-use formulation of IQ Hybridization Buffer. The result is higher signal-to-noise ratios in a less than 4-hour turnaround time, reducing the costs associated with labor and assays failures.

+ Expand

+ Expand

+ Expand

Contact Us
Part Number Production Description Volume
G111600-8 ALK IQFISH Break-Apart Probe 20 tests
G111601-8 ROS1 IQFISH Break-Apart Probe 20 tests
G111602-8 RET IQFISH Break-Apart Probe 20 tests
G111603-8 MET IQFISH Probe with CEP7 20 tests
G211600-8 ALK IQFISH Break-Apart Probe, 6 packs 6x20 tests
G211601-8 ROS1 IQFISH Break-Apart Probe, 6 packs 6x20 tests
G211602-8 RET IQFISH Break-Apart Probe, 6 packs 6x20 tests
G211603-8 MET IQFISH Probe with CEP7, 6 packs 6x20 tests
K5799 Dako Histology FISH Accessory Kit 20 tests

The Instructions for Use (IFU) above are in English, French and German. For IFUs in additional languages, please click and proceed to the next page:


The product referenced on this page are not available for sale in all countries or jurisdictions. The information contained in this website may not be valid in your jurisdictions. Please contact your local sales representative for additional information.

  1. Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448:561–66.
  2. Rikova K, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 131:1190–203.
  3. Takeuchi K, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. (2012) 18:378–81.
  4. Shaw AT, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. (2014) 371:1963–71.
  5. Cappuzzo F, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. (2009) 27:1667–7.
  6. Go H, et al. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. (2010) 5:305–13.